Please check your internet connection and try again.
# **Linagliptin**
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing the levels of incretin hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner.
## Primary Indications
* Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
* **Recommended Dose:** 5 mg orally once daily.
* Can be taken with or without food.
## Pediatric Dosing
* The safety and efficacy of linagliptin in pediatric patients have not been established.
## Dose Adjustments
* No dose adjustment is required for patients with mild, moderate, or severe renal impairment.
* No dose adjustment is required for patients with end-stage renal disease (ESRD) on hemodialysis or peritoneal dialysis.
* No dose adjustment is required for patients with hepatic impairment.
## Contraindications
* Known serious hypersensitivity to linagliptin or any excipient in the formulation.
## Adverse Effects
* **Common:** Nasopharyngitis, diarrhea, cough.
* **Serious:** Hypoglycemia (especially when used with insulin or sulfonylureas), severe and disabling arthralgia, angioedema, Stevens-Johnson syndrome, pancreatitis, acute renal failure.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Linagliptin is not a significant substrate of CYP3A4, CYP2C8, or CYP2C9, so interactions are unlikely.
* **Other Antidiabetic Agents:** Increased risk of hypoglycemia when used in combination with insulin or sulfonylureas. Dose reduction of the other agent may be necessary.
## Monitoring
* **HbA1c:** Regularly monitor glycemic control.
* **Renal Function:** Although dose adjustment is not needed, monitor as clinically indicated.
* **Signs and Symptoms of Pancreatitis:** Acute onset of persistent, severe abdominal pain, with or without nausea and vomiting.
* **Signs and Symptoms of Hypersensitivity Reactions:** Monitor for angioedema, rash, urticaria.
## Clinical Pearls
* Linagliptin does not require dose adjustment in renal or hepatic impairment, making it a convenient option for patients with these comorbidities.
* Consider the risk of hypoglycemia when co-administering with insulin or sulfonylureas.
* Educate patients on the signs and symptoms of pancreatitis and hypersensitivity reactions.
***
*Disclaimer: This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information or other relevant resources for the most current and comprehensive guidance.*
